To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Cost-effectiveness of cooled radiofrequency ablation vs. IAS injection for treatment of knee OA

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
August 2019

Cost-effectiveness of cooled radiofrequency ablation vs. IAS injection for treatment of knee OA

Vol: 8| Issue: 8| Number:21| ISSN#: 2564-2537
Study Type:Economic Analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data

BMC Musculoskelet Disord. 2019; 20: 302.

Contributing Authors:
M Desai A Bentley WA Keck T Haag RS Taylor H Dakin

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

151 patients with knee osteoarthritis (OA) pain were randomized to receive cooled radiofrequency ablation (CRFA) or intra-articular corticosteroid (IAS) injections. Patients in the IAS group were given the opportunity to cross over to CRFA treatment after 6 months, however these patients were not included in the CRFA group analysis. The primary outcome of interest was the cost per quality-adjusted...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue